| Basics |
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.
|
| IPO Date: |
June 23, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$250.59M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.51%
|
| Avg Daily Range (30 D): |
$0.03 | 4.78%
|
| Avg Daily Range (90 D): |
$0.03 | 5.28%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.32M |
| Avg Daily Volume (30 D): |
4.33M |
| Avg Daily Volume (90 D): |
9.98M |
| Trade Size |
| Avg Trade Size (Sh.): |
268 |
| Avg Trade Size (Sh.) (30 D): |
512 |
| Avg Trade Size (Sh.) (90 D): |
669 |
| Institutional Trades |
| Total Inst.Trades: |
985 |
| Avg Inst. Trade: |
$1.43M |
| Avg Inst. Trade (30 D): |
$.6M |
| Avg Inst. Trade (90 D): |
$1.15M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.27M |
| Avg Closing Trade (30 D): |
$2.22M |
| Avg Closing Trade (90 D): |
$2.22M |
| Avg Closing Volume: |
171.19K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.51
|
$-.07
|
$-.09
|
|
Diluted EPS
|
$-.51
|
$-.07
|
$-.09
|
|
Revenue
|
$ 31.21M
|
$ 1.26M
|
$ 26.55M
|
|
Gross Profit
|
$ 30.6M
|
$ 1.23M
|
$ 26.21M
|
|
Net Income / Loss
|
$ -177.3M
|
$ -25.3M
|
$ -33.77M
|
|
Operating Income / Loss
|
$ -177.46M
|
$ -25.68M
|
$ -32.74M
|
|
Cost of Revenue
|
$ .62M
|
$ .03M
|
$ .35M
|
|
Net Cash Flow
|
$ -33.61M
|
$ -3.77M
|
$ 32.11M
|
|
PE Ratio
|
|
|
|
|
